CU20220025A7 - Inihibidores del factor d del complemento para administración oral - Google Patents
Inihibidores del factor d del complemento para administración oralInfo
- Publication number
- CU20220025A7 CU20220025A7 CU2022000025A CU20220025A CU20220025A7 CU 20220025 A7 CU20220025 A7 CU 20220025A7 CU 2022000025 A CU2022000025 A CU 2022000025A CU 20220025 A CU20220025 A CU 20220025A CU 20220025 A7 CU20220025 A7 CU 20220025A7
- Authority
- CU
- Cuba
- Prior art keywords
- inhibitors
- oral administration
- complement factor
- complement
- factor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D307/80—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D307/81—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/22—Amides of acids of phosphorus
- C07F9/24—Esteramides
- C07F9/2454—Esteramides the amide moiety containing a substituent or a structure which is considered as characteristic
- C07F9/2475—Esteramides the amide moiety containing a substituent or a structure which is considered as characteristic of aralkylamines
Abstract
<p>Compuestos de las fórmulas (I)- (IV) y sales farmacéuticamente aceptables de los mismos, que son inhibidores del sistema del complemento. </p>
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962913021P | 2019-10-09 | 2019-10-09 | |
PCT/US2020/054922 WO2021072156A1 (en) | 2019-10-09 | 2020-10-09 | Oral complement factor d inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
CU20220025A7 true CU20220025A7 (es) | 2022-11-07 |
Family
ID=75438077
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CU2022000025A CU20220025A7 (es) | 2019-10-09 | 2020-10-09 | Inihibidores del factor d del complemento para administración oral |
Country Status (20)
Country | Link |
---|---|
EP (1) | EP4041717A1 (es) |
JP (1) | JP2022552186A (es) |
KR (1) | KR20220081341A (es) |
CN (1) | CN114555570A (es) |
AR (1) | AR120174A1 (es) |
AU (1) | AU2020361586A1 (es) |
BR (1) | BR112022006608A2 (es) |
CA (1) | CA3156269A1 (es) |
CL (1) | CL2022000889A1 (es) |
CO (1) | CO2022005926A2 (es) |
CR (1) | CR20220196A (es) |
CU (1) | CU20220025A7 (es) |
EC (1) | ECSP22036455A (es) |
IL (1) | IL291943A (es) |
JO (2) | JOP20220076A1 (es) |
MX (1) | MX2022004264A (es) |
PE (1) | PE20221152A1 (es) |
TW (1) | TW202128674A (es) |
UY (1) | UY38909A (es) |
WO (1) | WO2021072156A1 (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3148119A1 (en) * | 2019-07-31 | 2021-02-04 | Biocryst Pharmaceuticals, Inc. | Dosing regimens for oral complement factor d inhibitors |
WO2023066357A1 (zh) * | 2021-10-21 | 2023-04-27 | 江苏恒瑞医药股份有限公司 | 稠合环类化合物、其制备方法及其在医药上的应用 |
CN115403544A (zh) * | 2022-09-16 | 2022-11-29 | 台州永健医药科技有限公司 | 一种丹酚酸c的制备方法 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7919519B2 (en) * | 2005-11-23 | 2011-04-05 | Epix Pharmaceuticals Inc. | S1P receptor modulating compounds and use thereof |
WO2016088082A1 (en) * | 2014-12-05 | 2016-06-09 | Novartis Ag | Amidomethyl-biaryl derivatives complement factor d inhibitors and uses thereof |
TW202222786A (zh) * | 2016-02-01 | 2022-06-16 | 美商百歐克斯製藥公司 | 苯并吡唑化合物及其類似物 |
WO2019057946A1 (en) * | 2017-09-25 | 2019-03-28 | F. Hoffmann-La Roche Ag | MULTI-CYCLIC AROMATIC COMPOUNDS AS D-FACTOR INHIBITORS |
TW202010742A (zh) * | 2018-04-06 | 2020-03-16 | 美商百歐克斯製藥公司 | 取代的苯并呋喃、苯并吡咯、苯并噻吩及結構相關的補體抑制劑 |
-
2020
- 2020-10-08 UY UY0001038909A patent/UY38909A/es unknown
- 2020-10-08 TW TW109134972A patent/TW202128674A/zh unknown
- 2020-10-08 AR ARP200102783A patent/AR120174A1/es unknown
- 2020-10-09 CU CU2022000025A patent/CU20220025A7/es unknown
- 2020-10-09 IL IL291943A patent/IL291943A/en unknown
- 2020-10-09 CN CN202080070735.5A patent/CN114555570A/zh active Pending
- 2020-10-09 MX MX2022004264A patent/MX2022004264A/es unknown
- 2020-10-09 JP JP2022520898A patent/JP2022552186A/ja active Pending
- 2020-10-09 JO JOP/2022/0076A patent/JOP20220076A1/ar unknown
- 2020-10-09 KR KR1020227011586A patent/KR20220081341A/ko unknown
- 2020-10-09 JO JOP/2022/0077A patent/JOP20220077A1/ar unknown
- 2020-10-09 AU AU2020361586A patent/AU2020361586A1/en active Pending
- 2020-10-09 PE PE2022000584A patent/PE20221152A1/es unknown
- 2020-10-09 CR CR20220196A patent/CR20220196A/es unknown
- 2020-10-09 EP EP20875434.1A patent/EP4041717A1/en active Pending
- 2020-10-09 WO PCT/US2020/054922 patent/WO2021072156A1/en unknown
- 2020-10-09 CA CA3156269A patent/CA3156269A1/en active Pending
- 2020-10-09 BR BR112022006608A patent/BR112022006608A2/pt unknown
-
2022
- 2022-04-07 CL CL2022000889A patent/CL2022000889A1/es unknown
- 2022-05-05 CO CONC2022/0005926A patent/CO2022005926A2/es unknown
- 2022-05-06 EC ECSENADI202236455A patent/ECSP22036455A/es unknown
Also Published As
Publication number | Publication date |
---|---|
AR120174A1 (es) | 2022-02-02 |
BR112022006608A2 (pt) | 2022-06-28 |
JOP20220076A1 (ar) | 2023-01-30 |
CN114555570A (zh) | 2022-05-27 |
EP4041717A1 (en) | 2022-08-17 |
MX2022004264A (es) | 2022-06-08 |
TW202128674A (zh) | 2021-08-01 |
CL2022000889A1 (es) | 2022-11-11 |
CO2022005926A2 (es) | 2022-07-29 |
KR20220081341A (ko) | 2022-06-15 |
CR20220196A (es) | 2022-08-18 |
CA3156269A1 (en) | 2021-04-15 |
ECSP22036455A (es) | 2022-08-31 |
UY38909A (es) | 2021-05-31 |
IL291943A (en) | 2022-06-01 |
JOP20220077A1 (ar) | 2023-01-30 |
JP2022552186A (ja) | 2022-12-15 |
PE20221152A1 (es) | 2022-07-18 |
AU2020361586A1 (en) | 2022-05-19 |
WO2021072156A1 (en) | 2021-04-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2020000075A1 (es) | Carboxamidas como moduladores de los canales de sodio. | |
CU20220025A7 (es) | Inihibidores del factor d del complemento para administración oral | |
CL2018002410A1 (es) | Inhibidores de mcl-1 y métodos de uso de los mismos | |
CO2018008916A2 (es) | Compuestos de benzopirazol y análogos de estos | |
UY37710A (es) | Inhibidores de la replicación del virus de la inmunodeficiencia humana | |
CL2017000902A1 (es) | Dihidropirrolopiridinas inhibidoras de ror-gamma | |
DOP2020000102A (es) | Compuestos útiles para inhibir a cdk7 | |
CR20150463A (es) | Inhibidores de la ruta de quinurenina | |
CY1122024T1 (el) | Ενωσεις αναστολης σηματοδοτησης μονοπατιου notch | |
NI201900077A (es) | Inhibidores selectivos de jak1 | |
CL2022000875A1 (es) | Inhibidores del factor d del complemento para administración oral | |
CO2020013840A2 (es) | Benzofurano, benzopirrol, benzotiofeno sustituidos y otros inhibidores del complemento estructuralmente relacionados | |
AR101414A1 (es) | Derivados de pirrolidinona como inhibidores de metap-2 | |
UY39150A (es) | Pirrolopirimidinaminas como inhibidores del sistema del complemento | |
CL2020001020A1 (es) | Derivados de bencimidazol y sus usos. | |
CO2020004977A2 (es) | Compuestos bicíclicos para su uso como inhibidores de la ripi quinasa | |
CO2021007172A2 (es) | Sales cristalinas de un inhibidor de calicreína plasmática | |
CO2021001277A2 (es) | Inhibidores de triazol glicolato oxidasa | |
CU20160166A7 (es) | Compuestos derivados de n-(1,5-dimetil-3-oxo-2,3-dihidro-1h-pirazol-4-il)-4-metil-5-isoxazol-3-carboxamida activos como inhibidores selectivos de smurf-1 | |
CO2021004873A2 (es) | Inhibidores de o-glicoproteína-2-acetamido-2-desoxi-3-d-glucopiranosidasa | |
CO2023015732A2 (es) | Moduladores de trex1 | |
CU20190002A7 (es) | Combinación de un inhibidor de bcl-2 y un inhibidor de mcl1 para el tratamiento del cáncer y composiciones farmacéuticas que los comprenden | |
BR112018012030A2 (pt) | composição para redução da frequência de urinação, método de produção e uso da mesma |